A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Public ClinicalTrials.gov record NCT03750786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.
Study identification
- NCT ID
- NCT03750786
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 490 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2018
- Primary completion
- Nov 17, 2022
- Completion
- Nov 17, 2022
- Last update posted
- Oct 25, 2023
2018 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 840-24 - Banner Gateway Medical Center | Gilbert | Arizona | 85234 | — |
| 840-15 - University of Southern California | Los Angeles | California | 91001 | — |
| 840-01 - HOAG Memorial Hospital | Newport Beach | California | 92663 | — |
| 840-13 - UCH-MHS d/b/a Memorial Health System | Colorado Springs | Colorado | 80909 | — |
| 840-34 - Banner MD Anderson Cancer Center | Greeley | Colorado | 80631 | — |
| 840-32 - University of Miami | Miami | Florida | 33136 | — |
| 840-08 - Pinellas Hematology Oncology | St. Petersburg | Florida | 33709 | — |
| 840-30 - Joliet Oncology-Hematology Associates | Joliet | Illinois | 60435 | — |
| 840-06 - Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| 840-29 - Ashland-Bellefonte Cancer Center | Ashland | Kentucky | 41101 | — |
| 840-19 - University of Louisville Research Foundation Inc. (ULRF) | Louisville | Kentucky | 40202-1798 | — |
| 840-14 - University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| 840-04 - St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| 840-12 - Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| 840-22 - University of Oklahoma Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| 840-10 - Oregon Health and Science University-Knight Cancer Institute | Portland | Oregon | 97239 | — |
| 840-27 - Charleston Hematology Oncology Associates | Charleston | South Carolina | 29414 | — |
| 840-02 - The University of Texas Health Science Center | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
Recently updated Colo-rectal Cancer trials
Other public records listing Colo-rectal Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07620535: Decision Counseling and Follow-up for Shield+ Patients Not yet recruiting
- NCT05321134: Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery Recruiting
- NCT07058012: A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) Recruiting
- NCT07085091: A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors Recruiting
- NCT07345676: Colorectal Cancer Screening Outreach Not yet recruiting
- NCT06880055: Shield Post-Approval Study Protocol Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03750786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03750786 live on ClinicalTrials.gov.